This review includes recommendations for the treatment of common sexually transmitted infections (STIs) other than HIV and viral hepatitis in nonpregnant adolescents and adults. Some of the indications and dosages included here have not been approved by the FDA.
PARTNER TREATMENT — Sex partners of patients with an STI should be examined and tested for STIs if possible. Alternatively, clinicians can provide treatment for sex partners of their patients without direct examination or testing by either writing a prescription for the partner or giving the partner's medication to their patient, a practice called expedited...
- Pivmecillinam (Pivya) for Uncomplicated UTI
- Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
- Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
- In Brief: A Bumetanide Nasal Spray (Enbumyst) for Edema
- In Brief: Ranitidine Returns
- In Brief: Rybelsus R2 Rebranded as Ozempic
- In Brief: Optune Pax — A Portable Device for Pancreatic Cancer (online only)
ISSUE
The FDA has required that the labels of all carbidopa/levodopa-containing products (Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, Vyalev) include a warning about the risk of vitamin B6 (pyridoxine) deficiency and vitamin B6 deficiency-related seizures associated with their use. The combination of carbidopa/levodopa is the most effective treatment for the motor symptoms of Parkinson's disease and recent evidence favors its early use.1
Vitamin B6 is required for the conversion of levodopa to dopamine; high doses of levodopa can deplete vitamin B6 levels during the conversion process. Carbidopa also binds to the active form of vitamin B6.
The new warnings were based on a review that identified 14 cases of seizures, 2 of which were fatal, associated with vitamin B6 deficiency in patients receiving >1000 mg/day of oral or enteral carbidopa/levodopa. The seizures were generally focal-onset …